StreetInsider.com News Articles

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 12 Jun 2026 16:05:00 -0400

MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of June 12, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 12 Jun 2026 16:05:00 -0400

Form 8-K InspireMD, Inc. For: Jun 11

Thu, 11 Jun 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260611/26632952.html

Form 8-K InspireMD, Inc. For: Jun 11

Thu, 11 Jun 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260611/26632952.html

InspireMD reports 30-day trial results for carotid stent system

Thu, 11 Jun 2026 08:03:48 -0400

InspireMD Inc. (NASDAQ: NSPR) announced 30-day results from its CGUARDIANS II clinical trial evaluating the CGuard Prime 80cm implant for transcarotid artery revascularization procedures. The company has submitted a premarket approval supplement to the FDA, which is currently under review.

The trial enrolled 50 patients across 11 sites and achieved 100% acute device success with no deaths, strokes, or myocardial infarctions reported within 30 days. The study also showed no stent thrombosis and complete stent patency at 30 days in evaluable subjects.

Dr. Patrick J. Geraghty, professor of surgery and radiology at Washington University School of Medicine and co-lead investigator, said the

InspireMD reports 30-day trial results for carotid stent system

Thu, 11 Jun 2026 08:03:48 -0400

Dr. Patrick J. Geraghty, professor of surgery and radiology at Washington University School of Medicine and co-lead investigator, said the

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

Thu, 11 Jun 2026 08:00:00 -0400

PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures

MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year.

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

Thu, 11 Jun 2026 08:00:00 -0400

PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures

InspireMD enrolls first patient in pivotal neuro protection study

Mon, 08 Jun 2026 08:02:38 -0400

InspireMD Inc. (NASDAQ: NSPR) announced that the first patient has been enrolled in its CGUARDIANS III pivotal study of the SwitchGuard neuro protection system for use in transcarotid artery revascularization procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital in Cincinnati, Ohio.

The study will evaluate the safety and efficacy of the SwitchGuard neuro protection system combined with InspireMD's CGuard Prime 80 cm stent platform for treating carotid artery stenosis in patients at high risk for complications from carotid endarterectomy.

Dr. Muck and Dr. Patrick Geraghty from Washington University School of Medicine in St. Louis will serve as

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

Mon, 08 Jun 2026 08:00:00 -0400

MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio.

Dr. Muck and Dr. Patrick Geraghty, professor of surgery

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

Mon, 08 Jun 2026 08:00:00 -0400

Dr. Muck and Dr. Patrick Geraghty, professor of surgery

Form 8-K InspireMD, Inc. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598774.html

Form 8-K InspireMD, Inc. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598774.html

Form 4 InspireMD, Inc. For: May 27 Filed by: Stuka Paul

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575026.html

Form 4 InspireMD, Inc. For: May 27 Filed by: Stuka Paul

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575026.html

Form 8-K InspireMD, Inc. For: May 20

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541548.html

Form 8-K InspireMD, Inc. For: May 20

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541548.html

Form 4 InspireMD, Inc. For: Jan 27 Filed by: Gleason Shane Thomas

Thu, 21 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260521/26536870.html

Form 4 InspireMD, Inc. For: Jan 27 Filed by: Gleason Shane Thomas

Thu, 21 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260521/26536870.html

Form SCHEDULE 13G/A InspireMD, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260515/26507210.html

Form SCHEDULE 13G/A InspireMD, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 15 May 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260515/26507210.html

Form 4 InspireMD, Inc. For: May 13 Filed by: Stuka Paul

Fri, 15 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26505036.html

Form 4 InspireMD, Inc. For: May 13 Filed by: Stuka Paul

Fri, 15 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26505036.html

Form SCHEDULE 13G/A InspireMD, Inc. Filed by: Velan Capital Investment Management LP

Fri, 15 May 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26501511.html

Form SCHEDULE 13G/A InspireMD, Inc. Filed by: Velan Capital Investment Management LP

Fri, 15 May 2026 10:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26501511.html